The monomeric C-reactive protein level is associated with the increase in carotid plaque number in patients with subclinical carotid atherosclerosis

The high-sensitivity C-reactive protein (hsCRP) assay measures the level of the pentameric form of CRP in blood. Currently, there are no available assays measuring the level of the monomeric form of CRP (mCRP), produced at sites of local inflammation. We developed an assay measuring the mCRP level i...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cardiovascular medicine Vol. 9; p. 968267
Main Authors Melnikov, Ivan, Kozlov, Sergey, Pogorelova, Olga, Tripoten, Maria, Khamchieva, Leyla, Saburova, Olga, Avtaeva, Yuliya, Zvereva, Maria, Matroze, Evgeny, Kuznetsova, Tatiana, Prokofieva, Lyudmila, Balakhonova, Tatiana, Gabbasov, Zufar
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 22.07.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The high-sensitivity C-reactive protein (hsCRP) assay measures the level of the pentameric form of CRP in blood. Currently, there are no available assays measuring the level of the monomeric form of CRP (mCRP), produced at sites of local inflammation. We developed an assay measuring the mCRP level in blood plasma with functional beads for flow cytometry. The assay was used to measure the mCRP level in 80 middle-aged individuals with initially moderate cardiovascular SCORE risk. By the time of the mCRP measurement, the patients have been followed up for subclinical carotid atherosclerosis progression for 7 years. Ultrasound markers of subclinical atherosclerosis, which included plaque number (PN) and total plaque height (PH), were measured at baseline and at the 7th-year follow-up survey. Inflammatory biomarkers, including mCRP, hsCRP, inteleukin-6 (IL-6) and von Willebrand factor (VWF) level, were measured at the 7th-year follow-up survey. The median level of mCRP was 5.2 (3.3; 7.1) μg/L, hsCRP 1.05 (0.7; 2.1) mg/L, IL-6 0.0 (0.0; 2.8) pg/mL, VWF 106 (77; 151) IU/dL. In the patients with the mCRP level below median vs. the patients with the median mCRP level or higher, change from baseline in PN was 0.0 (0.0; 1.0) vs. 1.0 (1.0; 2.0) and PH 0.22 (−0.24; 1.91) mm vs. 1.97 (1.14; 3.14) mm, respectively ( p < 0.05). The adjusted odds ratio for the formation of new carotid atherosclerotic plaques was 4.7 (95% CI 1.7; 13.2) for the patients with the median mCRP level or higher. The higher mCRP level is associated with the more pronounced increase in PN and PH in patients with normal level of traditional inflammatory biomarkers and initially moderate cardiovascular SCORE risk.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Georgy Guria, National Research Centre for Haematology, Russia; Anton G. Kutikhin, Russian Academy of Medical Sciences, Russia
Edited by: Alexander Nikolaevich Orekhov, Institute for Aterosclerosis Research, Russia
This article was submitted to Atherosclerosis and Vascular Medicine, a section of the journal Frontiers in Cardiovascular Medicine
ISSN:2297-055X
2297-055X
DOI:10.3389/fcvm.2022.968267